Why Endogenous Biomarkers Need a Clearance Model
An endogenous biomarker is produced by the body rather than administered as a drug. If a renal transporter contributes to its elimination, inhibiting that transporter may change the biomarker’s plasma concentration or urinary excretion. These changes can provide evidence about transporter function without requiring the biomarker itself to be dosed.
The signal is not automatic, however. A plasma concentration reflects both production and all routes of elimination. Urinary excretion reflects the concentration reaching the kidney and the renal clearance that remains. Changes in production, filtration, other renal pathways, nonrenal clearance, or urine collection can therefore resemble or obscure a transporter effect.
All clearances must use the same concentration basis. For example, if clearance is defined relative to unbound plasma concentration, the production–clearance equations must also use unbound concentration. The model below treats the biomarker as a well-mixed amount represented by a single plasma concentration \(C\).
Steady-State Model and Its Assumptions
Let \(R\) denote the biomarker’s production rate, in amount per unit time. Assume constant production, linear clearance over the concentration range considered, and stable physiology during the comparison. At steady state, the production rate equals the sum of renal and nonrenal elimination rates. The urinary excretion rate \(U\) is the renal elimination rate, not the urine concentration.
Before inhibition, denote concentration and urinary excretion by \(C_0\) and \(U_0\). After inhibition, the transporter-sensitive component falls by \(I CL_T\), so that \(CL_{R,1}=CL_R-I CL_T\). If both the baseline and inhibited states have finite steady states, then
These equations require positive total clearance in each state. In particular, with positive production, the inhibited state has a finite steady concentration only if \(CL_R-I CL_T+CL_{NR}>0\). The assumptions also exclude rapid changes in production, renal function, urine flow effects on reabsorption, and transporter saturation. If such processes matter, these steady-state equations are not an adequate description.
Deriving the Expected Biomarker Changes
The concentration ratio follows by dividing the inhibited-state concentration by the baseline concentration. Production cancels only because it is assumed unchanged:
The quantity \(q\) is the fraction of baseline total clearance contributed by the inhibited pathway. Therefore, a given inhibition fraction \(I\) produces a larger concentration response when that pathway accounts for a larger share of total clearance. A small response does not, by itself, show that inhibition was weak: the pathway may simply contribute little to total clearance.
Urinary excretion changes according to both the concentration increase and the reduction in renal clearance. Dividing \(U_1=C_1(CL_R-I CL_T)\) by \(U_0=C_0CL_R\) gives
When \(CL_{NR}>0\) and \(CL_T>0\), \(q<r\), so \(U_1/U_0<1\) for \(I>0\): urinary excretion falls in this model. The increase in plasma concentration partly offsets the reduced renal clearance, but cannot fully offset it when some biomarker is eliminated nonrenally.
If \(CL_{NR}=0\) and \(0\le I<1\), the model predicts unchanged urinary excretion at steady state: all production still exits through the kidney, although plasma concentration rises. If \(I=1\) as well and all renal clearance is transporter-sensitive, then \(CL_R=CL_T\) and the inhibited total clearance is zero. With positive production, no finite steady state exists; the concentration formula has a zero denominator, and production cannot exit through the kidney. More generally, if \(CL_{NR}=0\), \(I=1\), and some renal clearance is unaffected, a finite steady state can still exist through that unaffected pathway.
Worked Example: Concentration and Excretion With Competing Routes
Suppose a hypothetical biomarker has \(R=20\) mg/h, baseline \(CL_R=6\) L/h, and \(CL_{NR}=4\) L/h. Of its renal clearance, \(CL_T=3\) L/h is transporter-sensitive. Assume \(I=0.50\), with unchanged production and all other model assumptions satisfied. Find the baseline and inhibited concentrations and urinary excretion rates.
At baseline, total clearance is \(6+4=10\) L/h, so \(C_0=20/10=2.00\) mg/L. Baseline urinary excretion is \(U_0=2.00\times6=12.0\) mg/h.
Inhibition removes \(I CL_T=0.50\times3=1.50\) L/h of renal clearance. Thus \(CL_{R,1}=6-1.50=4.50\) L/h and total inhibited clearance is \(4.50+4=8.50\) L/h. The new concentration is \(C_1=20/8.50=2.353\) mg/L. Urinary excretion is \(U_1=2.353\times4.50=10.59\) mg/h.
The concentration ratio is \(2.353/2.00=1.176\), an increase of about 17.6%. The excretion ratio is \(10.59/12.0=0.8825\), a decrease of about 11.8%. The concentration rises because total clearance falls; excretion falls because the loss of renal clearance is only partly offset by the higher concentration.
Baseline Variability and Paired Measurements
Endogenous biomarker values can vary between people and within one person over time. A single post-inhibition value is therefore difficult to interpret without a suitable baseline. A paired comparison—measuring each participant before and after the relevant change—controls stable differences between participants, although it does not remove time-varying production, renal function, or measurement error.
For positive concentrations, a log ratio is often useful because an increase and a decrease can be compared multiplicatively. For participant \(j\), define the log fold change as \(\ln(C_{1,j}/C_{0,j})\). The mean of these values estimates the mean log change; exponentiating it gives the geometric mean fold change. This summarizes a paired change but does not establish that the transporter caused it. A comparison condition, such as an appropriate control period, can help separate a drug-related change from time trends and ordinary variability.
Worked Example: Comparing Changes Against Within-Person Variability
In a hypothetical paired assessment, six participants have post-to-baseline concentration ratios of 1.18, 1.22, 1.10, 1.30, 1.15, and 1.25. Assume the participants are independent, their paired log ratios are approximately normally distributed, and the same biomarker assay and sampling conditions were used at both times. Calculate a confidence interval for the mean log change and interpret it.
The log ratios, rounded to four decimal places, are 0.1655, 0.1989, 0.0953, 0.2624, 0.1398, and 0.2231. Their mean is \(\bar{x}=0.1808\), and their sample standard deviation is \(s=0.0600\). The standard error is \(SE=s/\sqrt{n}=0.0600/\sqrt{6}=0.0245\). With \(df=5\), the two-sided 95% \(t\) critical value is approximately 2.571.
Exponentiating the endpoints gives \((e^{0.1179},e^{0.2438})=(1.125,1.276)\). The estimated geometric mean post-to-baseline concentration ratio is \(e^{0.1808}=1.198\), or about a 19.8% increase. Under the stated sampling assumptions, the interval gives plausible values for the population mean log ratio; expressed as fold changes, these are about 1.125 to 1.276. It is not a statement that there is a 95% probability that a fixed parameter lies in this particular interval. Nor does the interval identify transporter inhibition as the cause: that interpretation requires ruling out meaningful changes in production and competing clearance routes.
Baseline variability should be assessed on the scale relevant to the decision. Repeated baseline samples can reveal within-person variation; assay precision data can indicate whether changes are large relative to analytical error. A shift smaller than ordinary within-person fluctuation may be uninformative even if the mean change across a group is positive. Conversely, an apparent shift in one person is not strong evidence merely because it is numerically large when there is no reliable baseline estimate.
Worked Example: Why a Concentration Change Does Not Directly Give Inhibition
Consider a second hypothetical biomarker with baseline \(CL_R=8\) L/h, \(CL_{NR}=2\) L/h, and \(CL_T=4\) L/h. Let \(R=10\) mg/h. Suppose the observed concentration rises from 1.00 mg/L to 1.25 mg/L, and assume production and non-transporter clearances stayed constant. Use the model to estimate \(I\), then calculate the expected urinary excretion.
Baseline total clearance is \(8+2=10\) L/h, consistent with \(C_0=10/10=1.00\) mg/L. The observed concentration ratio is 1.25. The lost clearance is \(CL_R+CL_{NR}-R/C_1=10-10/1.25=2.00\) L/h. Since the lost clearance equals \(I CL_T\), \(I=2.00/4=0.500\).
The inhibited renal clearance is \(8-(0.500)(4)=6.00\) L/h. Thus \(U_0=1.00\times8=8.00\) mg/h, while \(U_1=1.25\times6.00=7.50\) mg/h. Excretion falls by \(0.50/8.00=6.25\%\). This estimate of \(I\) depends on the assumed model and on unchanged production and competing clearances; the concentration ratio alone cannot verify those assumptions.
Diagnostics, Comparisons, and Limitations
The model is a framework for interpreting evidence, not a guarantee that an observed change is transporter-specific. Check whether the biomarker has plausible transporter-mediated renal clearance and whether the direction of change agrees with the model. Compare plasma concentration with timed urinary excretion where possible. A spot urine concentration is not an excretion rate: it can change because urine volume or flow changes, even when the amount excreted per hour does not.
Useful diagnostics include repeated baseline measurements, consistent sampling times, reliable urine collection intervals, and checks for changes in renal function, hydration, production, or nonrenal elimination. A concentration increase without the expected urinary pattern may indicate a changed production rate, altered nonrenal clearance, measurement or collection problems, or a failure of the linear steady-state assumptions. Multiple endogenous biomarkers with different pathway contributions can strengthen interpretation, but their production and clearance characteristics must be considered separately.
| Approach | What it can show | Main limitation |
|---|---|---|
| Plasma concentration alone | A net change in the balance of production and total clearance | Does not isolate renal or transporter-mediated clearance |
| Timed urinary excretion alone | A change in the amount eliminated through the kidney per unit time | Depends on both plasma concentration and total renal clearance |
| Paired plasma and urine measurements | Whether concentration and renal elimination change in a pattern consistent with the model | Still depends on stable production, sound collection, and adequate pathway knowledge |
| Direct transporter or probe assessment | More targeted evidence about transporter activity under its own study assumptions | May not reflect the biomarker’s endogenous production or all in vivo pathways |
A further limitation is identifiability. The concentration ratio identifies the fractional change in total clearance only if production is known to be stable. It does not by itself distinguish which clearance pathway changed. Even with plasma and urine data, uncertainty in \(CL_T\), nonrenal clearance, and unaffected renal clearance can make the inhibition fraction \(I\) uncertain. The earlier material on identifiability of filtration, secretion, and reabsorption applies here in spirit: different combinations of pathway changes can produce similar aggregate observations.
Common Mistake
- Wrong reasoning: “Urinary excretion must stay constant during renal transporter inhibition because the biomarker is endogenous and its production is unchanged.”
- Correction: Constant production fixes total elimination at steady state, not the renal share of elimination. When nonrenal clearance is positive, the kidney can excrete less while nonrenal elimination accounts for more of the total. Unchanged urinary excretion follows in this model only when \(CL_{NR}=0\) and \(0\le I<1\). If \(I=1\) also eliminates all renal clearance, positive production cannot be balanced at a finite steady state.
Check Your Understanding
Use the model and assumptions in this tutorial. The questions are followed by concise solutions for checking your reasoning.
- If \(CL_R=5\) L/h, \(CL_{NR}=5\) L/h, and \(CL_T=2\) L/h, what is \(q\), the baseline fraction of total clearance attributable to the transporter-sensitive pathway?
- With positive \(CL_{NR}\), positive \(CL_T\), and \(I>0\), does the model predict urinary excretion to rise, fall, or remain unchanged at steady state?
- Why is a spot urine concentration not interchangeable with a timed urinary excretion rate?
- If \(CL_{NR}=0\), \(CL_R=CL_T\), and \(I=1\), what does the model predict for positive production?
Solutions. (1) \(q=2/(5+5)=0.200\). (2) It falls, because \(q<r\) and \(U_1/U_0=(1-Ir)/(1-Iq)<1\). (3) Spot concentration depends on urine volume and flow; timed excretion measures amount per unit time. (4) Total clearance becomes zero, so positive production cannot be balanced and no finite steady state exists.